OncoVista Innovative Therapies Inc., of San Antonio, initiated a preclinical safety study of OVI-117, an L-Nucleoside conjugate for solid tumors, in a second animal species. The company also is preparing to submit an investigational new drug application and plans to begin Phase I trials by the end of the year.